Detection and treatment of CD30+ cancers

  • US 10,444,241 B2
  • Filed: 02/08/2013
  • Issued: 10/15/2019
  • Est. Priority Date: 02/10/2012
  • Status: Active Grant
First Claim
Patent Images

1. A method of identifying a patient as eligible for CD30-directed therapy and administering the CD30 directed therapy to a patient thereby identified as eligible, wherein the patient has ovarian serous carcinoma, triple negative breast cancer, pancreatic carcinoma, small cell lung cancer, anal squamous cell carcinoma, anaplastic thyroid carcinoma, genitourinary squamous cell carcinoma, Leydig cell tumor or Sertoli cell tumor, the method comprising fixing a tissue sample obtained from the patient, wherein the sample comprises cells of the cancer or carcinoma, contacting the fixed tissue sample with an anti-CD30 antibody, and detecting binding of the antibody to the fixed tissue sample to determine CD30 is expressed in the sample, and identifying the patient as eligible for CD30-directed therapy based on the expression of CD30 in at least 10% of the malignant or atypical cells of the cancer or carcinoma in the sample or for a patient with pancreatic cancer or small cell lung cancer at least 45% of the malignant or atypical cells of the cancer in the sample;

  • and administering the CD30-directed therapy to the patient identified as eligible, wherein the CD30 directed therapy is therapy with an anti-CD30 antibody conjugated to an auristatin or DNA minor groove binding agent.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×